


RealRate

PHARMACEUTICAL 2022

Vanda Pharmaceuticals Inc. Rank 55 of 466









PHARMACEUTICAL 2022





Vanda Pharmaceuticals Inc. Rank 55 of 466

The relative strengths and weaknesses of Vanda Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Vanda Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 4.1% points.

The company's Economic Capital Ratio, given in the ranking table, is 264%, being 186% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	478,301
Cost of Goods Sold	0
Intangible Assets	20,081
Liabilities, Current	74,419
Liabilities, Non-Current	14,445
Other Assets	92,297
Other Compr. Net Income	-414
Other Expenses	36,319
Other Liabilities	0
Other Net Income	0
Other Revenues	268,881
Property and Equipment	3,113
Research and Development	75,363
Selling, General and Administrative Expense	124,047

Output Variable	Value in 1000 USD
Assets	593,792
Liabilities	88,864
Expenses	235,729
Revenues	268,881
Stockholders Equity	504,928
Net Income	33,152
Comprehensive Net Income	32,945
Economic Capital Ratio	264%

